C-LECTA
23.9.2022 09:36:37 CEST | Business Wire | Press release
OFB Projektentwicklung has started the first construction phase of the “BioSquare Leipzig” on a partial area of around 11,600 m² of the construction site 6a on the street “Alte Messe.” The symbolic groundbreaking ceremony on September 22, 2022, took place in the presence of Thomas Dienberg (Mayor for Urban Development and Construction of the City of Leipzig), Dr. Marc Struhalla (CEO of c-LEcta GmbH) and Dr. Christoph Wiechmann (Office Manager for Leipzig at OFB Projektentwicklung). The ceremony marks the start of a modern campus for biotechnology and the life sciences that comprises several buildings. The excavation of around 35,000 m³ of soil is scheduled to be completed by mid-November this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220923005032/en/
From left to right: Dr. Marc Struhalla (CEO of c-LEcta GmbH), Dr. Christoph Wiechmann (OFB Leipzig) and Thomas Dienberg (Mayor for Urban Development and Construction of the City of Leipzig).
As early as February 2022, a facade competition was held for the project with five architectural firms and a jury consisting of politicians, architects, scientists, the tenant c-LEcta and OFB. The Leipzig-based firm KLM Architekten und Ingenieure GmbH has now been commissioned as building planner for the first construction phase with the facade design.
Above ground, the first construction phase consists of two independent buildings with a total of around 18,500 m² of rental space. Five floors are planned for Building A, which will be used by the biotechnology company c-LEcta GmbH in the future and will have around 10,500 m² of above-ground rental space.
c-LEcta has been located at the “Alte Messe” site since the company was founded in 2004, and moved into its headquarters in the BioCube in 2012. The company has changed significantly since then: What began as a university spin-off with five employees has now evolved into a leading global player in industrial biotechnology. In 2021, c-LEcta worked with over 400 customers from more than 40 countries in the food and pharmaceutical industries, and once again significantly increased its sales compared to the previous year. Along with this, the number of employees has also developed rapidly over the years. Since 2018 alone, the number has doubled to 120 employees. Further growth in the workforce is also planned in the years ahead, so there will not be enough space available for the office and laboratory space in the current building.
The neighboring Building B in the direction of Prager Strasse comprises seven stories and thus offers a view over the old trade fair grounds after their completion. The slight offset of the second building will create a forecourt that provides an inviting access to building B with a good quality stay. Furthermore, a shared underground parking garage with around 110 parking spaces is being built.
Construction work on c-Lecta’s new corporate headquarters is scheduled for completion in the first half of 2025. In the second building of the first construction phase, another 8,000 m² of rental space is being created. With floor heights of four meters and modern construction grids, both buildings offer maximum flexibility in terms of use, so that both office space and laboratory space can be realized.
“The BioSquare project development underscores Leipzig’s importance as an innovation center for biotechnology and the life sciences. We want to keep innovative companies in these future industries at the location and attract new ones. Of course, we are particularly pleased that c-LEcta, a Leipzig success story, is moving into the first construction phase,” said the mayor and alderman for Urban Development and Construction of the City of Leipzig, Thomas Dienberg.
“The groundbreaking ceremony for our new headquarters in Leipzig is obviously a very special moment. In 2025, we will move into a high-tech building here with state-of-the-art workplaces and laboratories. This will not only secure sufficient space for further development in the long term, but at the same time provide a state-of-the-art design concept for our employees. Collaboration, concentrated work and regeneration go hand in hand. We are pleased to be able to continue our history at our home location,” emphasized Dr. Marc Struhalla, CEO of the tenant c-LEcta.
Dr. Christoph Wiechmann, head of OFB’s Leipzig office, is also quite pleased: “It is great to see that the excavators are now turning and the realization phase of BioSquare has begun. The ‘Alte Messe’ has made a name for itself as a location for innovative companies. On our campus, we offer research institutions and technology companies completely new development opportunities and perfect framework conditions.”
The project site is located within sight of the well-known double M of the Leipzig Mustermesse. The neighboring S-Bahn station “Völkerschlachtdenkmal” as well as several streetcar and bus lines offer very good public transport connections. The freeway ring road can also be reached in less than five minutes. Several innovative research institutions and companies such as the Fraunhofer IZI, the Max Planck Institute, Bio-City or the German Center for Integrative Biodiversity Research (iDiv) have settled at the “Alte Messe” location in recent years.
OFB: WE CONTINUE TO DEVELOP.
OFB Projektentwicklung GmbH has been in the real estate business for over 60 years. And is still as committed as on the first day. As a subsidiary of Landesbank Hessen-Thüringen and part of the Helaba Immobiliengruppe, high-quality and sustainable large-scale real estate is our focus. Project development, project management and real estate management are our passion.
At our headquarters in Frankfurt/Main and in our branches in Berlin, Erfurt, Munich, Düsseldorf and Leipzig, around 140 employees realize successful real estate projects throughout Germany. In doing so, we want to work harder than others – and therefore take the interaction of economic, ecological and social components into account as early as the planning stage of our projects. The goal: to develop our projects further, and ourselves as well.
About c-LEcta
c-LEcta is a global biotechnology company specializing in the development, production and distribution of enzyme products. The company uses world-class enzyme engineering and production technologies to provide its partners in the food and pharmaceutical industries with superior biotechnological solutions for innovative industrial applications. Product development is based on the proprietary enzyme technology platform ENESYZ® and is carried out both in-house and in close cooperation with industry partners worldwide. c-LEcta supplies its products to more than 400 customers in over 40 countries. c-LEcta currently employs more than 120 people at its headquarters in Leipzig.
c-LEcta is part of the Kerry Group. Kerry is the world’s leading taste and nutrition partner for the food, beverage and pharmaceutical markets. The company employs 22,000 people across over 150 locations and uses its broad range of ingredient solutions to innovate with its customers and create great tasting products, with improved nutrition and functionality, while ensuring a better impact for the planet.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220923005032/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom